Empirical Bioscience Elects Genome-Sequencing Exec to Board
Empirical Bioscience’s newest board member has more than 18 years of experience in genome sequencing.
Grand Rapids-based Empirical Bioscience, which recently changed its name from Syzygy Biotech, said last month that Richard Leach — vice president of business development at Complete Genomics in Mountain View, Calif. — has been elected to its board of directors.
Empirical Bioscience is a supplier of molecular biology reagents that act as fundamental components for life science activities involving DNA, such as genome sequencing, translational research, agricultural applications, clinical diagnostics and education.
Empirical Bioscience said Leach’s longtime work on genome sequencing and its application in fields such as personalized medicine will give the company “an unparalleled perspective on how to grow its existing and prospective markets for reagents used in polymerase chain reactions of human, animal and plant DNA.”
Leach previously served as vice president at deCODE genetics and as a scientific and business consultant at Shady Grove Center for Preimplantation Genetics.
Leach also presented “The Rise of Genomic Medicine” at last year’s TEDxGrandRapids event.
Leach holds a B.S. in biology and chemistry from Hillsdale College and a Ph.D. in molecular biology from Ohio University,
“He brings an international perspective and an authentic understanding of human genome sequencing that will keep us on the right track in this rapidly evolving industry,” said Craig Pippel, Empirical Bioscience board chairman. “We think Rick will prove to be an invaluable resource as we bring Empirical Bioscience to its full potential.”